1. Dear Drugs-Forum readers: We are a small non-profit that runs one of the most read drug information & addiction help websites in the world. We serve over 4 million readers per month, and have costs like all popular websites: servers, hosting, licenses and software. To protect our independence we do not run ads. We take no government funds. We run on donations which average $25. If everyone reading this would donate $5 then this fund raiser would be done in an hour. If Drugs-Forum is useful to you, take one minute to keep it online another year by donating whatever you can today. Donations are currently not sufficient to pay our bills and keep the site up. Your help is most welcome. Thank you.
    PLEASE HELP

2-Substituted Tryptamines: Agents with Selectivity for 5-HT6 Serotonin Receptors

2-Substituted Tryptamines: Agents with Selectivity for 5-HT6 Serotonin Receptors

  1. Anonymous
    J. Med. Chem. 2000, 43, 1011-1018
    Glennon et al.

    Several 2-alkyl-5-methoxytryptamine analogues were designed and prepared as potential 5-HT6 serotonin agonists. It was found that 5-HT6 receptors accommodate small alkyl substituents at the indole 2-position and that the resulting compounds can bind with affinities comparable to that of serotonin. In particular, 2-ethyl-5-methoxy-N,N-dimethyltryptamine (8) binds with high affinity at human 5-HT6 receptors (Ki ) 16 nM) relative to 5-HT (Ki ) 75 nM) and was a full agonist, at least as potent (8: Kact ) 3.6 nM) as serotonin (Kact ) 5.0 nM), in activating adenylate cyclase. Compound 8 displays modest affinity for several other populations of 5-HT receptors, notably h5-HT1A (Ki ) 170 nM), h5-HT1D (Ki ) 290 nM), and h5-HT7 (Ki ) 300 nM) receptors, but is otherwise quite selective. Compound 8 represents the first and most selective 5-HT6 agonist reported to date. Replacing the 2-ethyl substituent with a phenyl group results in a compound that retains 5-HT6 receptor affinity (i.e., 10: Ki ) 20 nM) but lacks agonist character. 2-Substituted tryptamines, then, might allow entry to a novel class of 5-HT6 agonists and antagonists.